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Reply to the letter to the editor
‘Can ovarian suppression with
gonadotropin releasing hormone
analogs (GnRHa) preserve fertility
in cancer patients?’ by
Rodriguez-Wallberg et al.
We thank Rodriguez-Wallberg et al. [1] for their interest in our
meta-analysis of randomized studies that assessed the role of
gonadotropin-releasing hormone analogs (GnRHa) as a strategy
to prevent chemotherapy-induced premature ovarian failure
(POF) and preserve fertility of premenopausal women with
breast cancer [2].
The authors expressed their concerns on the interpretation of
our results due to the lack of information on anticancer treat-
ment administered, the heterogeneity observed among studies,
the lack of comparison according to number of patients
attempting to become pregnant, and the limited data in terms of
disease-free survival (DFS). As we acknowledged, our meta-ana-
lysis is not based on individual patient data; hence, it was not
possible to investigate the impact of type and dose of chemo-
therapy administered and use of adjuvant endocrine therapy.
Despite the heterogeneity among studies, when restricting the
analysis to the trials reporting number of patients with regular
menses 1 year after the end of chemotherapy and number of
those who achieved pregnancy, the results were statistically sig-
nificant in favor of the use of GnRHa, with no heterogeneity. As
recently reported [3], the most valid denominator for comparing
pregnancy outcomes is the entire population as performed in
our study, since the number of patients attempting pregnancy
might be influenced by the intervention assignment and some
pregnancies might occur also in women who did not report an
attempt to become pregnant. Despite the limited data on DFS,
we did not find any difference between patients undergoing con-
current chemotherapy and GnRHa and those receiving chemo-
therapy alone. In the POEMS study, a statistically significant
improved DFS was observed in patients receiving concurrent
GnRHa and chemotherapy [3]. These results are also supported
by the excellent survival outcomes of patients enrolled in the
TEXT study who received concurrent ovarian suppression and
chemotherapy [4].
Rodriguez-Wallberg et al. criticized the exclusion of patients
with lymphoma. The reason was that patients with lymphoma
are different from those with breast cancer: they are character-
ized by young age at diagnosis, and some of them are candidates
to receive anticancer treatments with low gonadotoxic potential
(e.g. ABVD regimen). In this setting, the majority of patients
resume ovarian function at the end of chemotherapy irrespective
of the use of GnRHa. Long-term follow-up data of the available
randomized studies in this setting are warranted to assess
the potential role of GnRHa in preserving fertility and delaying
age at menopause.
Rodriguez-Wallberg et al. mentioned the meta-analysis by
Elgindy et al. showing no significant increase in ovarian func-
tion resumption with the use of this strategy. However, these
findings should be considered with caution due to several study
limitations: the inclusion of patients with different types of
cancer, the use of a different definition of POF than those used
in each eligible study, the possible biased weighting strategy
applied, and mainly the exclusion of some randomized trials
[5].
Finally, the authors suggested that GnRHa-induced gonadal
suppression has proved ineffective in men. Very limited data
exist on the efficacy of this strategy in men, for whom the
standard strategy for fertility preservation is semen cryopreser-
vation, a widely available, relatively cheap and not-time con-
suming procedure. Moreover, spermatogonia are much more
sensitive to the cytotoxic effects of chemotherapy when com-
pared with primordial oocytes and spermatogenesis is not a
cyclic event, thus making recovery of gonadal function less
plausible.
To conclude, a growing amount of data coming from ran-
domized, controlled studies, suggest the efficacy of temporary
ovarian suppression with GnRHa during chemotherapy to
preserve both ovarian function and fertility. As recently
endorsed by the National Comprehensive Cancer Network
guidelines (www.nccn.org) and the 2015 St Gallen
International Expert Consensus panel [6], this strategy
should be offered to young premenopausal breast cancer
patients interested in preserving their ovarian function fol-
lowing chemotherapy.
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Integration between oncology
and palliative care: does one size
fit all?
For the very first time, the article of Hui et al. sets up indicators
of integration of oncology and palliative care programmes: they
consider as ‘major’ indicators of integration the presence of a
‘palliative care inpatient consultation team’ and a ‘palliative care
outpatient clinic’ [1].
The authors of the article report data from a previous survey
showing how in the United States, among centres which are not
designated by the National Cancer Institute—and as such, not
specifically working in oncology—only 56% have a ‘palliative
care inpatient consultation’ and 22% an ‘outpatient clinic’ [2].
If this is an image of how things work in a country—the
United States—with an advanced health care system, may we be
entitled to scale the same criteria to most other countries in the
world—even if not having the same logistical standards and
favourable economical frame?
The real world is not made of big hospitals, with great
resources, in rich countries. On the contrary, most cancer
patients are followed in small centres, many of which are located
in developing countries.
Among the above-mentioned indicators, we miss the presence
of ‘community-based palliative care services’, which are import-
ant, most of all, in small and/or remote communities, yet the
authors say that few panellists work within such settings.
This supports our belief, that these indicators are designed for
a ‘rich’ setting, faraway from the real world. Indeed, the same
authors state that to meet these integration indicators we need
‘proper funding’, and we know this is not available in most on-
cology programmes in the world.
That said, we are fully convinced of the value of Hui et al.
work, yet we believe that it can be introduced only in advanced
health systems with great economical resources.
Besides, we hope for an expert panel determining ‘basic’ criteria
for integration of oncology and palliative care; criteria that could
help developing sustainable integration programmes, taking into
account centres with limited resources and foreseeing a key role
for ‘community-based palliative care services’.
For this, it would be necessary to propose goals (e.g. evalu-
ation and treatment of symptoms, continuity of care, non-aban-
donment at end-of-life, etc.) rather than pre-set models, so that
each single centre is able to develop ‘tailored’ programmes to
their own resources.
According to our experience, it is possible to build custom-
tailored programmes for each single economical, cultural, and
geographical situation, bearing in mind that, when we talk
about health services, ‘one size does not fit all’ [3, 4].
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Reply to the letter to the editor
‘Integration between oncology
and palliative care: does one size
fit all?’ by Verna et al.
We would like to thank Verna et al. [1] for their thoughtful
comments regarding our recent Annals of Oncology article on
the 13 major and 30 minor indictors of integration of oncology
and palliative care programs in hospitals with ≥100 beds [2].
They commented on the need to have indicators specific for re-
source-limited settings, and the importance of community-
based palliative care programs.
When we first designed this study, we recognized that indica-
tors are highly specific to the health care setting and local
resources. Thus, we explicitly asked our panelists to identify
indictors of integration for advanced cancer patients in hospitals
with ≥100 beds [2]. Remarkably, a vast majority of the indica-
tors were supported by our international panelists despite their
diverse background representing six continents. The major indi-
cators were endorsed by over 90% of panelists, suggesting that
there may be some universal themes of integration beyond na-
tionalities, disciplines and cultures.
The need for integration is independent of resource availabil-
ity and further studies are needed to examine indicators of inte-
gration specific for low-resource settings. In a recent systematic
review, we identified several other aspects of integration [3]. For
example, the availability of opioid may be an appropriate indicator
in low-resource countries, while a comprehensive home palliative
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